Hepion Pharmaceuticals Future Growth
Future criteria checks 0/6
Hepion Pharmaceuticals's earnings are forecast to decline at 33.4% per annum while its annual revenue is expected to grow at 85.7% per year.
Key information
-33.4%
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth | 22.8% |
Revenue growth rate | 85.7% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 21 Nov 2023 |
Recent future growth updates
Recent updates
Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely
Aug 10We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate
Apr 25We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate
Oct 27Hepion Pharma rises as company begins NASH treatment trial
Aug 31Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?
Jul 04Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH
Feb 17Hepion Pharmaceuticals: Facing The Momentous Year 2022
Jan 21Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug
Sep 21Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth
Sep 14Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race
Sep 08Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)
May 26What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?
Feb 18Hepion Pharma cleared to advance final dosing cohort in NASH trial
Dec 29Hepion Pharma to begin CRV431 testing in COVID-19 patients
Dec 22Dosing underway in higher dose cohort with Hepion's CRV431 in NASH study
Dec 10Hepion Pharma prices equity offering at $1.50
Nov 25Hepion Pharmaceuticals (HEPA) Investor Presentation - Slideshow
Oct 31Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -90 | N/A | N/A | 1 |
12/31/2025 | N/A | -76 | N/A | N/A | 1 |
12/31/2024 | N/A | -52 | N/A | N/A | 1 |
12/31/2023 | N/A | -49 | -41 | -41 | N/A |
9/30/2023 | N/A | -48 | -37 | -37 | N/A |
6/30/2023 | N/A | -46 | -38 | -38 | N/A |
3/31/2023 | N/A | -52 | -33 | -33 | N/A |
12/31/2022 | N/A | -45 | -35 | -35 | N/A |
9/30/2022 | N/A | -45 | -38 | -38 | N/A |
6/30/2022 | N/A | -46 | -36 | -36 | N/A |
3/31/2022 | N/A | -34 | -34 | -34 | N/A |
12/31/2021 | N/A | -33 | -31 | -31 | N/A |
9/30/2021 | N/A | -28 | -29 | -28 | N/A |
6/30/2021 | N/A | -25 | -21 | -21 | N/A |
3/31/2021 | N/A | -22 | -19 | -19 | N/A |
12/31/2020 | N/A | -20 | -16 | -16 | N/A |
9/30/2020 | N/A | -18 | -14 | -14 | N/A |
6/30/2020 | N/A | -13 | -12 | -12 | N/A |
3/31/2020 | N/A | -15 | -10 | -10 | N/A |
12/31/2019 | N/A | -12 | -8 | -8 | N/A |
9/30/2019 | N/A | -12 | -10 | -10 | N/A |
6/30/2019 | N/A | -20 | -12 | -12 | N/A |
3/31/2019 | N/A | -17 | -14 | -14 | N/A |
12/31/2018 | N/A | -18 | -16 | -16 | N/A |
9/30/2018 | N/A | -17 | -13 | -13 | N/A |
6/30/2018 | N/A | -14 | -15 | -15 | N/A |
3/31/2018 | N/A | -8 | -16 | -16 | N/A |
12/31/2017 | N/A | -13 | -18 | -18 | N/A |
9/30/2017 | N/A | -16 | N/A | -20 | N/A |
6/30/2017 | N/A | -15 | N/A | -19 | N/A |
3/31/2017 | N/A | -22 | N/A | -19 | N/A |
12/31/2016 | N/A | -18 | N/A | -18 | N/A |
9/30/2016 | N/A | -17 | N/A | -18 | N/A |
6/30/2016 | N/A | -17 | N/A | -17 | N/A |
3/31/2016 | N/A | -17 | N/A | -16 | N/A |
12/31/2015 | N/A | -21 | N/A | -15 | N/A |
9/30/2015 | N/A | -26 | N/A | -11 | N/A |
6/30/2015 | N/A | -22 | N/A | -10 | N/A |
3/31/2015 | N/A | -12 | N/A | -6 | N/A |
12/31/2014 | N/A | -14 | N/A | -4 | N/A |
9/30/2014 | N/A | -7 | N/A | -2 | N/A |
6/30/2014 | N/A | -5 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HEPA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HEPA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HEPA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HEPA is forecast to have no revenue next year.
High Growth Revenue: HEPA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HEPA's Return on Equity is forecast to be high in 3 years time